Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC(2)-NY-ESO-1/TRICOM + INCB024360 in Ovarian Cancer
NCT01982487Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2013
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Small Molecules
01
Overview
A Phase 2 trial of epacadostat, ALVAC(2)-NY-ESO-1(M) + TRICOM in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Dec 2013; status: withdrawn.
02
Drugs
epacadostatALVAC(2)-NY-ESO-1(M) + TRICOM
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01982487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982487.